FibroGen Inc
NASDAQ:FGEN
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
US |
FibroGen Inc
NASDAQ:FGEN
|
119.4m USD | -0.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 12.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 20.8 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.1B USD | 28.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109B USD | 23 | ||
AU |
CSL Ltd
ASX:CSL
|
134.1B AUD | 33.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.4B USD | 9.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
54.2B USD | -18.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -79.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.9B USD | 20 | ||
KR |
Celltrion Inc
KRX:068270
|
38.6T KRW | 71.8 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.